Division of Gastroenterology and Hepatology, University of Calgary, Calgary, Alberta, Canada; Robarts Clinical Trials, Inc, London, Ontario, Canada.
Robarts Clinical Trials, Inc, London, Ontario, Canada.
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1904-1908. doi: 10.1016/j.cgh.2018.10.004. Epub 2018 Oct 4.
Fistulizing complications develop in approximately one third of patients with Crohn's disease (CD), resulting in morbidity and impaired quality of life. Sites of fistulae most commonly include perianal fistulae, but also enterocutaneous, enteroenteric, enterovesical, and rectovaginal. Its management requires combined medical and surgical strategies to prevent abscess formation and induce healing. Biologic agents have improved the medical treatment of CD-related fistulae, but many patients still require surgical intervention. Hence, there is considerable interest in the development of novel pharmaceutical agents to treat fistulizing CD.
约三分之一的克罗恩病（CD）患者会出现瘘管并发症，导致发病率和生活质量受损。瘘管最常见的部位包括肛周瘘管，但也有肠皮瘘、肠肠瘘、肠膀胱瘘和直肠阴道瘘。其治疗需要结合内科和外科策略，以防止脓肿形成和促进愈合。生物制剂改善了 CD 相关瘘管的内科治疗，但许多患者仍需要手术干预。因此，人们对开发新型药物治疗瘘管性 CD 产生了浓厚的兴趣。
